Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D C	20540
wasiiiigton,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Johnson-Pratt Lisa</u>				2. Issuer Name and Ticker or Trading Symbol Tracon Pharmaceuticals, Inc. [ TCON ]							(Ch	elationship of the contract of	able)	g Perso	on(s) to Issu 10% Ow			
(Last)	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 04/19/2023							Officer below)	(give title		Other (spelow)	pecify		
C/O TRACON PHARMACEUTICALS, INC. 4350 LA JOLLA VILLAGE DRIVE, STE 800				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person							
(Street) SAN DII	EGO CA	A	92122									Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)		$ _{\sqcap}$	Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instalting the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,			Code (In:	ransaction Disposed Of (D) (Instr. 3, 2)			ed (A) or tr. 3, 4 and	5. Amour Securitie Beneficia Owned F Reported	es Featly (I	Form:	Direct C Indirect E str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	/	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			msu. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Cc	ransaction of ode (Instr. Derivative		ive ies ed ed ed	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Co	Date Expiration Code V (A) (D) Exercisable Date Title				Title	Amount or Number of Shares								
Director Stock Option (Right to Buy)	\$1.82	04/19/2023			A		18,000		(1)	04	4/18/2033	Common Stock	18,000	\$0.00	18,000		D	

## **Explanation of Responses:**

1. The shares subject to the option shall vest and become exercisable on the earlier of the first anniversary of the grant date set forth in column 3 above or the date of the next annual meeting of the Company's stockholders, subject to the optionee's Continuous Service (as defined in the Company's 2015 Equity Incentive Plan (the "Plan")) and accelerated on the closing of a Change of Control (as defined in the Plan).

## Remarks:

/s/ Scott B. Brown, Attorney-

04/21/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.